DeepMind announced on Oct 15, 2026 that its Antigravity workbench was used to identify a new antimicrobial peptide in Streptococcus pseudopneumoniae. The platform’s AI model ProtNLM scans millions of unannotated UniProt proteins and predicts function from raw amino‑acid sequences. In a single interactive session, a biologist and the AI narrowed the search to a high‑confidence lead, which is now being validated in wet‑lab experiments. The system also includes a 3D viewer that syncs with the AI for structural analysis.
Why it matters
If validated, the peptide could become a new drug option for doctors treating resistant respiratory infections.
